title: [Drug UDCA (Ursosan) in therapeutic management of patients Barrett's esophagus].
abstract: OBJECTIVE
  to evaluate the five-year prospective study the possibility of using the drug UDCA (Ursosan) for the therapeutic management of patients with BE older.
  
  
  METHODS
  A prospective open randomized, parallel-group 62 patients of BE with a length of metaplasia less than 3 cm in average age 72.8 +/- 2.8 years. Method of "sealed envelopes" were divided into two equal groups. Patients first--received omeprazole at a daily dose of 40 mg, the second--to combine the same dose of omeprazole drug-Ursosan a daily dose of 10 mg/kg. At baseline and after 4.8+1.2 years assessed the frequency of esophageal, extraesophageal and dyspeptic complaints, endoscopic and morphological pattern of esophageal-gastric junction and lower third of the esophagus. Confirm or exclude the diagnosis of BE during follow-up study was performed after a two-fold endoscopy upper GIT using subdivision techniques for sampling biopsy material and subsequent analysis of biopsy samples pathomorphology of various medical institutions.
  
  
  RESULTS
  The combination therapy with omeprazole and drug UDCA contributed to the positive dynamics is the lack of intestinal metaplasia in 32.3% of patients with Barrett's esophagus, whereas monotherapy with omeprazole in a daily dose of 40 mg possible to achieve a similar result in 6.5% of patients (p = 0,01). The frequency of diagnosis of erosive esophagitis decreased after 5 years of therapy with 80.6% to 51.6% (p = 0.016) in the omeprazole group and 86.7% to 16.7% (p < 0.001) in the group receiving omeprazole and the preparation of UDCA.
  
  
  CONCLUSIONS
  This study suggests the possibility of combined therapy with omeprazole and the preparation of UDCA (Ursosan) as a promising means for hemopreventciya Barrett's esophagus in the elderly.
authors.forename: E V
authors.initials: EV
authors.lastname: Onuchina
authors.forename: V V
authors.initials: VV
authors.lastname: Tsukanov
authors.forename: M F
authors.initials: MF
authors.lastname: Osipenko
mesh_terms: D000367:Age Factors; D000368:Aged; D000897:Anti-Ulcer Agents / Q000008:administration & dosage; D001471:Barrett Esophagus / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D002756:Cholagogues and Choleretics / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009853:Omeprazole / Q000008:administration & dosage; D011446:Prospective Studies; D014580:Ursodeoxycholic Acid / Q000008:administration & dosage* / Q000031:analogs & derivatives*
chemical_list: D000897:Anti-Ulcer Agents; D002756:Cholagogues and Choleretics; D014580:Ursodeoxycholic Acid; D009853:Omeprazole